nach oben

Erschienen in:

01.01.2009 | Laboratory Investigation - human/animal tissue

Motexafin gadolinium enhances the efficacy of aminolevulinic acid mediated-photodynamic therapy in human glioma spheroids

verfasst von: Steen J. Madsen, Marlon S. Mathews, Even Angell-Petersen, Chung-Ho Sun, Van Vo, Rogelio Sanchez, Henry Hirschberg

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Photodynamic therapy (PDT) has been investigated as a postoperative treatment in patients with high grade gliomas. The purpose of this in vitro investigation was to determine whether motexafin gadolinium (MGd), a known radiation sensitizer, could potentiate the effects of 5-aminolevulinic acid (ALA)-PDT. Human glioma (ACBT) spheroids (250 μm diameter) were incubated in 5-aminolevulinic acid (ALA) with and without MGd and irradiated with 635 nm light for a total light fluence of 6, 12, or 18 J cm⁻² delivered at a fluence rate of 5 mW cm⁻². Spheroid growth was monitored for a period of 4 weeks following each treatment. In another set of experiments, 400–500 μm diameter ACBT spheroids were implanted into a gel collagen matrix and subjected to ALA-PDT (fluence: 3 or 6 J cm⁻²), MGd, or a combination of ALA-PDT and MGd. The migration distance of surviving glioma cells in each treatment group was recorded over a 5-day period. The results showed that MGd interacted with PDT in a synergistic manner resulting in greater cytotoxicity than that achievable with either treatment modality alone. The degree of synergism was shown to increase with increasing light fluence. At the highest light fluence investigated (18 J cm⁻²), the percentage of spheroids demonstrating growth 4 weeks following exposure to MGd, ALA-PDT, or MGd + ALA-PDT was 100%, 75%, and 15%, respectively. The results of cell migration studies revealed that the combination of PDT and MGd produced a significant inhibitory effect on glioma cell migration: the addition of MGd resulted in an approximately three times reduction in migration distance compared with PDT alone. Overall, the results suggest that MGd can potentiate both the cytotoxic and migration inhibitory effects of ALA-PDT and hence, this combined therapeutic approach has the potential to extend treatment volumes in patients with malignant gliomas.

Stupp R, van den Bent MJ, Hegi ME (2005) Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5:198–206. doi:10.1007/s11910-005-0047-7 PubMedCrossRef

Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG (1989) Patterns of failure following treatments for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409PubMed

Muller PJ, Wilson BC, Lilge LD, Yang V, Hetzel FW, Chen Q et al (2001) Photofrin photodynamic therapy for malignant brain tumors. In: Dougherty TJ (ed) Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy. Proceedings SPIE, vol 4248, April 2001, SPIE Publishers, Bellingham, WA, pp 34–41

Eljamel MS, Goodman C, Moseley H (2007) ALA and Photofrin® fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre phase III randomised controlled trial. Lasers Med Sci. doi:10.1007/s10103-007-0494-2

Beck TJ, Kreth FW, Beyer W, Mehrkens JH, Obermeier A, Stepp H et al (2007) Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg Med 39(5):386–393. doi:10.1002/lsm.20507 PubMedCrossRef

Dougherty TJ (1993) Photodynamic therapy. Photochem Photobiol 58:895–900. doi:10.1111/j.1751-1097.1993.tb04990.x PubMedCrossRef

Lilge L, Wilson BC (1998) Photodynamic therapy of intracranial tissues: a preclinical comparative study of four different photosensitizers. J Clin Laser Med Surg 16:81–92PubMed

Hebeda KM, Saarnak AE, Olivo M, Sterenborg HJ, Wolbers JG (1998) 5-Aminolevulinic acid induced endogenous porphyrin fluorescence in 9L and C6 brain tumours and in the normal rat brain. Acta Neurochir (Wien) 140:503–513. doi:10.1007/s007010050132 CrossRef

Lilge L, Portnoy M, Wilson BC (2000) Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumor tissue. Br J Cancer 83:1110–1117. doi:10.1054/bjoc.2000.1426 PubMedCrossRef

10.

Obwegeser A, Jakober R, Kostron H (1998) Uptake and kinetics of 14C-labelled meta-tetrahydroxylchlorin and 5-aminolevulinic acid in the C6 rat glioma model. Br J Cancer 78:733–738PubMed

11.

Stummer W, Stocker S, Novotny A, Heimann A, Sauer O, Kempski O et al (1998) In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. J Photochem Photobiol B Biol 45:160–169. doi:10.1016/S1011-1344(98)00176-6 CrossRef

12.

Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C et al (1998) Intraoperative detection of malignant gliomas by 5-aminolevulinic acid induced porphyrin fluorescence. Neurosurgery 42:518–526. doi:10.1097/00006123-199803000-00017 PubMedCrossRef

13.

Terr L, Weiner LP (1983) An autoradiographic study of 5-aminolevulinic acid uptake by mouse brain. Exp Neurol 79:564–568. doi:10.1016/0014-4886(83)90234-0 PubMedCrossRef

14.

Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93:1003–1013PubMedCrossRef

15.

Angell-Petersen E, Hirschberg H, Madsen SJ (2007) Determination of fluence rate and temperature distributions in the rat brain; implications for photodynamic therapy. J Biomed Opt 12(1):014003-1–014003-9CrossRef

16.

Sessler JL, Burrell AK (1992) Expanded porphyrins. Top Curr Chem 161:177–273

17.

Magda D, Miller RA (2006) Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol 16(6):466–476. doi:10.1016/j.semcancer.2006.09.002 PubMedCrossRef

18.

Evens AM (2004) Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol 16(6):576–580. doi:10.1097/01.cco.0000142073.29850.98 PubMedCrossRef

19.

Madsen SJ, Sun C-H, Tromberg BJ, Wallace VP, Hirschberg H (2000) Photodynamic therapy of human glioma spheroids using 5-aminolevulinic acid. Photochem Photobiol 72(1):128–134. doi:10.1562/0031-8655(2000)072<0128:PTOHGS>2.0.CO;2PubMedCrossRef

20.

Sutherland RM, Carlsson J, Durand RE, Yuhas J (1981) Spheroids in cancer research. Cancer Res 41:2980–2994

21.

Drewinko B, Loo TL, Brown B, Gottlieb JA, Freireich EJ (1976) Combination therapy in vitro with adriamycin: observation of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells. Cancer Biochem Biophys 1:187–195PubMed

22.

Hirschberg H, Sun C-H, Krasieva T, Madsen SJ (2006) Effects of ALA-mediated photodynamic therapy on the invasiveness of human glioma cells. Lasers Surg Med 38:939–945. doi:10.1002/lsm.20445 PubMedCrossRef

23.

Mathews MS, Sun C–H, Madsen SJ, Hirschberg H (2007) Comparing the effects of repetitive and chronic PDT in human glioma spheroids. In: Kollias N, Choi B, Zeng H et al (eds) Photonic therapeutics and diagnostics III. Proceedings SPIE, vol 6424, SPIE Publishers, Bellingham, WA, pp D1–D9

24.

Madsen SJ, Sun C-H, Tromberg BJ, Hirschberg H (2003) Repetitive 5-aminolevulinic acid-mediated photodynamic therapy on human glioma spheroids. J Neurooncol 62(3):243–250. doi:10.1023/A:1023362011705 PubMedCrossRef

25.

Giese A, Loo MA, Tran N, Haskett D, Coons SW, Berens ME (1996) Dichotomy of astrocytoma migration and proliferation. Int J Cancer 67:275–282. doi:10.1002/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9PubMedCrossRef

26.

Giese A, Loo MA, Rief MD, Tran N, Berens ME (1995) Substrates for astrocytoma invasion. Neurosurgery 37:294–302. doi:10.1097/00006123-199508000-00015 PubMedCrossRef

27.

Binder DK, Berger MS (2002) Proteases and the biology of glioma invasion. J Neurooncol 56:149–158. doi:10.1023/A:1014566604005 PubMedCrossRef

28.

Rao JS (2000) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3(7):489–501. doi:10.1038/nrc1121 CrossRef

29.

Uhm JH, Dooley NP, Villemure JG, Yong VW (1997) Mechanisms of glioma invasion: role of matrix-metalloproteinases. Can J Neurol Sci 24:3–15PubMed

30.

Koul D, Parthasarathy R, Shen R, Davies MA, Jasser SA, Chintala SK et al (2001) Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20:6669–6678. doi:10.1038/sj.onc.1204799 PubMedCrossRef

31.

Maidment SL (1997) The cytoskeleton and brain tumour cell migration. Anticancer Res 17:4145–4149PubMed

32.

Chicoine MR, Silbergeld DL (1995) Assessment of brain tumor cell motility in vivo and in vitro. J Neurosurg 82:615–622PubMed

33.

Muller PJ, Wilson BC (1986) An update on the penetration depth of 630 nm light in normal and malignant human brain tissue in vivo. Phys Med Biol 31:1295–1297. doi:10.1088/0031-9155/31/11/012 PubMedCrossRef

34.

Wilson BC, Jeeves WP, Lowe DM (1985) In vivo and post mortem measurements of the attenuation spectra of light in mammalian tissues. Photochem Photobiol 42:153–162. doi:10.1111/j.1751-1097.1985.tb01554.x PubMedCrossRef

35.

Doiron DR, Svaasand LO, Profio AE (1983) Light dosimetry in tissue applications to photoradiation therapy. In: Kessel D, Dougherty TJ (eds) Porphyrin photosensitization. Plenum Press, New York, pp 63–75

36.

Powers SK, Brown JT (1986) Light dosimetry in brain tissue: an in vivo model applicable to photodynamic therapy. Lasers Surg Med 6:318–322. doi:10.1002/lsm.1900060305 PubMedCrossRef

37.

Chen Q, Chopp M, Madigan L, Dereski MO, Hetzel FW (1996) Damage threshold of normal rat brain in photodynamic therapy. Photochem Photobiol 64:163–167. doi:10.1111/j.1751-1097.1996.tb02437.x PubMedCrossRef

38.

Madsen SJ, Sun C-H, Tromberg BJ, Hirschberg H (2001) Development of a novel indwelling balloon applicator for optimizing light delivery in photodynamic therapy. Lasers Surg Med 29:406–412. doi:10.1002/lsm.10005 PubMedCrossRef

39.

Bisland SK, Lilge L, Lin A, Rusnow R, Wilson BC (2004) Metronomic photodynamic therapy as a new paradigm for photodynamic therapy: rationale and preclinical evaluation of technical feasibility for treating malignant brain tumors. Photochem Photobiol 80:22–30. doi:10.1562/2004-03-05-RA-100.1 PubMedCrossRef

40.

Sessler JL, Miller RA (2000) Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 59:733–739. doi:10.1016/S0006-2952(99)00314-7 PubMedCrossRef

41.

Khuntia D, Mehta M (2004) Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 4:981–989. doi:10.1586/14737140.4.6.981 PubMedCrossRef

42.

Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB et al (2001) Multicenter phase IB/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19:2074–2083PubMed

43.

Hirschberg H, Wu GN, Madsen SJ (2007) Evaluation of motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI. Minim Invasive Neurosurg 50:1–6. doi:10.1055/s-2007-993158 CrossRef

44.

Donnelly ET, Liu YF, Fatunmbi YO, Lee I, Magda D, Rockwell S (2004) Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors. Int J Radiat Oncol Biol Phys 58(5):1570–1576. doi:10.1016/j.ijrobp.2003.12.017 PubMedCrossRef

45.

Wu GN, Ford JM, Alger JR (2006) MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain. J Neurooncol 77:95–103. doi:10.1007/s11060-005-9101-1 PubMedCrossRef

46.

Hirschberg H, Sørensen DR, Angell-Petersen E, Peng Q, Tromberg B, Sun CH et al (2006) Repetitive photodynamic therapy of malignant brain tumors. J Environ Pathol Toxicol Oncol 25(1–2):261–280PubMed

47.

Viala J, Vanel D, Meingan P, Lartigau E, Carde P, Renschler MF (1999) Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology 212:755–759PubMed

48.

Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA et al (2002) Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445–3453. doi:10.1200/JCO.2002.07.500 PubMedCrossRef

49.

Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W et al (2003) Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21(13):2529–2536. doi:10.1200/JCO.2003.12.122 PubMedCrossRef

50.

Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T et al (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22(1):157–165. doi:10.1200/JCO.2004.05.128 PubMedCrossRef

51.

Rosenthal DI, Nurenberg P, Becerra CR, Frenkel EP, Carbone DP, Lum BL et al (1999) A phase I single dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 5:739–745PubMed

52.

Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA (1999) In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 45(4):981–989. doi:10.1016/S0360-3016(99)00274-6 PubMed

53.

De Stasio G, Rajesh D, Ford JM, Daniels MJ, Erhardt RJ, Frazer BH et al (2006) Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei. Clin Cancer Res 12(1):206–213. doi:10.1158/1078-0432.CCR-05-0743 PubMedCrossRef

54.

Woodburn KW (2001) Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J Pharmacol Exp Ther 297:888–894PubMed

55.

Hirschberg H, Mathews MS, Angell-Petersen E, Spetalen S, Madsen SJ (2007) Increased brain edema following 5-aminolevulinic acid administration mediated photodynamic therapy in normal and tumor-bearing rats. In: Kollias N, Choi B, Zeng H et al (eds) Photonic therapeutics and diagnostics III. Proceedings SPIE, vol 6424, SPIE Publishers, Bellingham, WA, pp B1–B8

56.

Hirschberg H, Zhang M, Chighvinadze D, Peng Q, Madsen SJ (2008) Targeted opening of the blood brain barrier by ALA mediated PDT. In: Kollias N, Choi B, Zeng H et al (eds) Photonic therapeutics and diagnostics IV. Proceedings SPIE, vol 6842, SPIE Publishers, Bellingham, WA, pp O1–O11

57.

Madsen SJ, Angell-Petersen E, Spitalen S, Carper SW, Ziegler S, Hirschberg H (2006) Photodynamic therapy of newly implanted glioma cells in the rat brain. Lasers Surg Med 38:540–548. doi:10.1002/lsm.20274 PubMedCrossRef

58.

Madsen SJ, Kharkhuu K, Hirschberg H (2007) Utility of the F98 rat glioma model for photodynamic therapy. J Environ Pathol Toxicol Oncol 26(2):149–155PubMed

59.

Madsen SJ, Sun C-H, Tromberg BJ, Yeh AT, Sanchez R, Hirschberg H (2002) Effects of combined photodynamic therapy and ionizing radiation on human glioma spheroids. Photochem Photobiol 76:411–416. doi:10.1562/0031-8655(2002)076<0411:EOCPTA>2.0.CO;2PubMedCrossRef

60.

Hirschberg H, Sun C-H, Yeh AT, Tromberg BJ, Madsen SJ (2004) Enhanced effects of concurrent 5-aminolevulinic acid-mediated photodynamic therapy by hyperthermia on human glioma spheroids. J Neurooncol 70:289–299. doi:10.1007/s11060-004-9161-7 PubMedCrossRef

61.

Iinuma S, Farshi SS, Ortel B, Hasan T (1994) A mechanistic study of cellular photodestruction with 5-aminolevulinic acid-induced porphyrin. Br J Cancer 70:21–28PubMed

62.

Verma A, Facchina SL, Hirsch DJ, Song S-Y, Dillahey LF, Williams JR et al (1998) Photodynamic tumor therapy: mitochondrial benzodiazepine receptors as a therapeutic target. Mol Med 4:40–48PubMed

Titel: Motexafin gadolinium enhances the efficacy of aminolevulinic acid mediated-photodynamic therapy in human glioma spheroids
verfasst von: Steen J. Madsen
Marlon S. Mathews
Even Angell-Petersen
Chung-Ho Sun
Van Vo
Rogelio Sanchez
Henry Hirschberg
Publikationsdatum: 01.01.2009
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2009
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-008-9692-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Aberrant MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation in choroid plexus tumors

Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients

Hypofractionated stereotactic radiotherapy in combination with whole brain radiotherapy for brain metastases

Bone marrow transplantation for severe aplastic anemia secondary to temozolomide

Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma